Diabetes and cancer relationships

被引:23
作者
Wang, Tiange [1 ,2 ,3 ]
Ning, Guang [1 ,2 ,3 ]
Bloomgarden, Zachary [4 ]
机构
[1] Minist Hlth, Key Lab Endocrine & Metab Dis, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Shanghai Clin Ctr Endocrine & Metab Dis, Shanghai 200030, Peoples R China
[3] Shanghai Univ E Inst, Shanghai, Peoples R China
[4] Mt Sinai Sch Med, Dept Med, 35 East 85th St, New York, NY 10028 USA
关键词
cancer; diabetes; diabetes treatment; epidemiology; randomized controlled trial; GROWTH-FACTOR-I; INSULIN-RECEPTOR ISOFORM; SHORT-TERM INCIDENCE; ALL-CAUSE MORTALITY; BODY-MASS INDEX; SERUM C-PEPTIDE; BREAST-CANCER; IGF-I; PROSTATE-CANCER; COLORECTAL-CANCER;
D O I
10.1111/1753-0407.12057
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes and cancer are both heterogeneous and multifactorial diseases with tremendous impact on health worldwide. Epidemiologic evidence suggests that certain malignancies may be associated with diabetes, as well as with diabetes risk factors and, perhaps, with certain diabetes treatments. Numerous biological mechanisms could account for these relationships. Insulin-like growth factor (IGF)-1, IGF-2, IGF-1 receptors, insulin, and the insulin receptor play roles in the development and progression of cancers. Although evidence from randomized controlled trials does not support or refute associations of diabetes and its treatments with either increased or reduced risk of cancer incidence or prognosis, consideration of malignancy incidence rates and the magnitude of the trials that would be required to address these issues explains why such studies may not be readily undertaken.
引用
收藏
页码:378 / 390
页数:13
相关论文
共 167 条
[1]   Structure and function of the type 1 insulin-like growth factor receptor [J].
Adams, TE ;
Epa, VC ;
Garrett, TPJ ;
Ward, CW .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (07) :1050-1093
[2]   Cancer Incidence and Mortality After Gastric Bypass Surgery [J].
Adams, Ted D. ;
Stroup, Antoinette M. ;
Gress, Richard E. ;
Adams, Kenneth F. ;
Calle, Eugenia E. ;
Smith, Sherman C. ;
Halverson, R. Chad ;
Simper, Steven C. ;
Hopkins, Paul N. ;
Hunt, Steven C. .
OBESITY, 2009, 17 (04) :796-802
[3]   Understanding the Mechanism of Insulin and Insulin-Like Growth Factor (IGF) Receptor Activation by IGF-II [J].
Alvino, Clair L. ;
Ong, Shee Chee ;
McNeil, Kerrie A. ;
Delaine, Carlie ;
Booker, Grant W. ;
Wallace, John C. ;
Forbes, Briony E. .
PLOS ONE, 2011, 6 (11)
[4]   Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people [J].
Andersson, Charlotte ;
Vaag, Allan ;
Selmer, Christian ;
Schmiegelow, Michelle ;
Sorensen, Rikke ;
Lindhardsen, Jesper ;
Gislason, Gunnar H. ;
Kober, Lars ;
Torp-Pedersen, Christian .
BMJ OPEN, 2012, 2 (03)
[5]  
[Anonymous], 2007, Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective
[6]   Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus A Systematic Review and Meta-analysis [J].
Barone, Bethany B. ;
Yeh, Hsin-Chieh ;
Snyder, Claire F. ;
Peairs, Kimberly S. ;
Stein, Kelly B. ;
Derr, Rachel L. ;
Wolff, Antonio C. ;
Brancati, Frederick L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (23) :2754-2764
[7]   Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort [J].
Baur, Dorothee M. ;
Klotsche, Jens ;
Hamnvik, Ole-Petter R. ;
Sievers, Caroline ;
Pieper, Lars ;
Wittchen, Hans-Ulrich ;
Stalla, Guenter K. ;
Schmid, Roland M. ;
Kales, Stefanos N. ;
Mantzoros, Christos S. .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (10) :1363-1371
[8]  
Becker Susen, 2009, Archives of Physiology and Biochemistry, V115, P86, DOI 10.1080/13813450902878054
[9]   Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer [J].
Belfiore, A ;
Pandini, G ;
Vella, V ;
Squatrito, S ;
Vigneri, R .
BIOCHIMIE, 1999, 81 (04) :403-407
[10]   The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level [J].
Ben Sahra, I. ;
Laurent, K. ;
Loubat, A. ;
Giorgetti-Peraldi, S. ;
Colosetti, P. ;
Auberger, P. ;
Tanti, J. F. ;
Le Marchand-Brustel, Y. ;
Bost, F. .
ONCOGENE, 2008, 27 (25) :3576-3586